Blueprint Medicines (BPMC) Tops Q2 EPS by 3c

Blueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($0.70), $0.03 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $7.07 million versus the consensus estimate of $4.41 million.

Financial Guidance:

Blueprint Medicines expects that its cash, cash equivalents and investments balance will be at least $120 million at December 31, 2016. Blueprint Medicines expects that its existing cash, cash equivalents and investments will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into early 2018.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
• Nike names former Pfizer CFO David Denton as new finance chief